T-cell redirector
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for T-cell redirector, covering 2026-03-17 to 2026-03-17. Get the full timeline:
Most recent: Clinical Trial Update: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma [Phase 2]